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Synthesis of chloroquine analogues 
Chloroquine (CQ) analogues with side alkyl amino side chain variation were synthesized via 
substitution reaction of an appropriate amine and 4,7-dichloroquinoline.1  CQ analogues of ring-size 
variations and ring-substituent variations were synthesized similarly using an appropriate quinoline or 
pyridine derivative as starting materials.   
Synthesis of CQ4a.  A mixture of 4,7-dichloroquinoline (619 mg, 3.1 mmol) and  1,5-
dimethylhexylamine (3.1 g, 23.7 mmol) was heated at 100 °C for 1 h and then at 155 °C for 3 h.  The 
reaction was monitored by TLC to ensure the completion of reaction.  Unreacted amines were distilled 
under vacuum and could be reused.  The resulting brownish residue was applied to a silica gel flash 
column and a solvent mixture (CHCl3/CH3OH /Et3N (25/1/1)) was used as eluent.  CQ4a was isolated in 
64% yield after combining elution fractions. CQ4a was further purified by crystallization (CHCl3 and 
hexane) to give 120 mg (13% yield) of white solid.  1H NMR (CDCl3) δ 8.52 (1H, d, 1-Ar-H), 7.95 (1H, 
d, 5-Ar-H), 7.64 (1H, d, 8-Ar-H), 7.37 (1H, dd, 6-Ar-H), 6.42 (1H, d, 2-Ar-H), 4.78 (1H, br, Ar-NH), 3.71 
(1H, m, -NHCH(CH3)CH2CH2CH2CH(CH3)CH3), 1.67-1.43 (5H, m, -NHCH(CH3)CH2CH-
2CH2CH(CH3)CH3), 1.32 (3H, d, -NHCH(CH3)CH2CH2CH2CH(CH3)CH3), 1.23 (2H, d, -
NHCH(CH3)CH2CH2CH2CH(CH3)CH3), 0.87 (6H, d, -NHCH(CH3)CH2CH2CH2CH(CH3)CH3).  
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Synthesis of CQ4b.  4,7-Dichloroquinoline (1.98g, 10 mmol) and L-alanine (1.78 g, 20 mmol) were 
heated in phenol (8 g) for one hour at 160 °C.  The solution was poured into a solution mixture of 10% KI 
(30 mL) and ethyl ether (30 mL).  The aqueous layer was then washed with ether layer (3×30 mL).  The 
combined ether layer was extracted with 10% KI (30 mL).  The pH of the combined aqueous phase was 
adjusted to 7.  The aqueous solution was let uncovered for slow evaporation at room temperature.  After 
about 24 h, white crystals were filtered and dried under vacuum (1.25g, 55%).  1H NMR (CD3OD) δ 8.43 
(1H, d, 1-Ar-H), 8.33 (1H, d, 5-Ar-H), 7.76 (1H, d, 8-Ar-H), 7.56 (1H, dd, 6-Ar-H), 6.66 (1H, d, 2-Ar-H), 
4.26 (1H, m, NHCH(CH3)COOH ), 1.66 (3H, d, NHCH(CH3)COOH) 
Synthesis of CQ4c.  CQ4c was synthesized using the same method as CQ4a with corresponding 
amine (26%).  1H NMR (CDCl3) δ 8.53 (1H, d, 1-Ar-H), 7.94 d (1H, dd, 5-Ar-H), 7.70 (1H, d, 8-Ar-H), 
7.36 (1H,  dd, 6-Ar-H), 6.35 (1H, d, 2-Ar-H),  5.92 (1H, br., Ar-NH), 3.28 (2H, t, -NHCH2CH2N(CH3)2), 
2.68 (2H, t, -NHCH2CH2N(CH3)2), 2.30 (6H, s, -NHCH2CH2N(CH3)2).     
Synthesis of CQ4d.  4,7-Dichloroquinoline (620 mg, 3.1mmol) and N1-isopropyl-diethylenetriamine 
(1.76g, 12.3 mmol) was heated for 1 h at 100 °C and then for additional 3 h at 155 °C.  TLC analysis 
indicated that 4,7-Dichloroquinoline was completely consumed after 4 h.  Unreacted amine was distilled 
at 85-115 °C using a Kugelrohr apparatus under a vacuum of approximately 50 millitorr. The remaining 
brown oil was transferred to a silica gel flash column.  A solvent mixture (CH2Cl2/CH3OH/NH4OH 
(70/28/2), 200 mL) was used as eluent, followed by another eluent (CH2Cl2/CH3OH/NH4OH (5/20/4), 
200 mL).  The fractions containing CQ4d (Rf = 0.1  in CH2Cl2/NH4OH/CH3OH (40/1.5/80)) were 
collected, combined and subjected to another silica gel column separation (CHCl3/CH3OH /Et3N (10/1/1), 
200 mL) to give a pale yellow oil (35%). 1H NMR (CD3CD) δ 8.52 (1H, d, 1-Ar-H), 7.94 (1H, d, 8-Ar-H), 
7.70 (1H, d, 5-Ar-H), 7.35 (1H, dd, 6-Ar-H), 6.32 (1H, d, 2-Ar-H), 5.98 (1H, br., Ar-NH), 3.36-2.07 (12H, 
m, -NHCH2CH2NHCH2CH2NHCH(CH3)2), 1.07 (6H, d, -NHCH2CH2NHCH2CH2NHCH(CH3)2). 
  
 
S2 
 
Synthesis of CQ4e.  4,7-Dichloroquinoline (500mg, 2.5 mmol) and excess 1,4-piperazine-
dipropanamine (5 g, 25 mmol) were heated for 12 h at 135 °C.  TLC analysis indicated that 4,7-
Dichloroquinoline was completely consumed after 12 h reaction.  Unreacted amine was distilled at 85-110 
°C using a Kugelrohr apparatus under a vacuum of approximately 50 millitorr. The remaining brown oil 
was transferred to a silica gel flash column.  A solvent mixture (CH2Cl2/CH3OH/NH4OH (70/28/2), 800 
mL) was used as eluent, followed by elution in CH2Cl2/CH3OH/NH4OH ((5/20/4), 200 mL) and 
CH3OH/NH4OH ((1/1), 200 mL).   Three different compounds were observed on TLC 
(CH2Cl2/CH3OH/NH4OH (5/20/4)). The fraction with Rf = 0.33 was found to be CQ4e. The combined 
fractions were transferred to another silica-gel column and eluted with (CHCl3/CH3OH/Et3N (10/1/1), 200 
mL) for another time. Clean fractions were obtained and combined.  Solvent was removed under vacuum 
to give a colorless oil (31%).  1H NMR (CD3CD) δ 8.35 (1H, d, 1-Ar-H), 8.07 (1H, d, 5-Ar-H), 7.77 (1H, 
d, 8-Ar-H), 7.39 (1H, dd, 6-Ar-H), 6.53 (1H, d, 2-Ar-H), 3.39 (2H, t, -
NHCH2CH2CH2N(CH2CH2)2NCH2CH2CH2NH2), 2.41-2.69 (14H, m, -
NHCH2CH2CH2N(CH2CH2)2NCH2CH2CH2NH2), 1.93 (2H, m, -
NHCH2CH2CH2N(CH2CH2)2NCH2CH2CH2NH2), 1.64 (2H, m, -
NHCH2CH2CH2N(CH2CH2)2NCH2CH2CH2NH2).     
Synthesis of CQ4f.  4,7-Dichloroquinoline (680 mg, 3.4 mmol) and excess of Tris-(2-aminoethyl)-
amine (5 g, 34 mmol) were heated for 12 h at 135 °C.  TLC analysis indicated that 4,7-Dichloroquinoline 
was completely consumed after 12 h reaction.  Unreacted amine was distilled at 85-110 °C using a 
Kugelrohr apparatus under a vacuum of approximately 50 millitorr. The remaining brown oil was 
transferred to a silica gel flash column.   A solvent mixture (CH2Cl2/CH3OH/NH4OH (70/28/2), 800 mL) 
was used as eluent, followed by elution with CH2Cl2/CH3OH/NH4OH ((5/20/4), 200 mL) and 
CH3OH/NH4OH ((1/1), 200 mL).   Three different compounds were observed on TLC 
(CH2Cl2/CH3OH/NH4OH (5/20/4)). The fraction with Rf = 0.2 was identified to be CQ4f. The combined 
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fractions with Rf = 0.2 were transferred to another column and eluted with (CHCl3/CH3OH/NH4OH 
(20/5/1), 200 mL). Clean fractions were collected and combined.  Solvent was removed under vacuum to 
give a colorless oil (15%). 1H NMR (CDCl3) δ 8.50 (1H, d, 1-Ar-H), 7.98 (1H, d, 5-Ar-H), 7.92 (1H, d, 8-
Ar-H), 7.32 (1H, dd, 6-Ar-H), 6.69 (1H, br, Ar-NH), 6.35 (1H, d, 2-Ar-H), 3.36 (2H, m, -
NHCH2CH2N(CH2CH2NH2)2), 2.89-2.68 (6H, m, -NHCH2CH2N(CH2CH2NH2)2), 2.63 (4H, t, -
NHCH2CH2N(CH2CH2NH2)2), 1.59 (5H, br, -NHCH2CH2N(CH2CH2NH2)2). 
Synthesis of CQ7a.  4-chloro-7-trifluoromethyl quinoline (0.5g, 2.16 mmol) and 2-amino-5-
diethylaminopentane (2.61 g, 15.7 mmol) were heated together at 100 °C for 1 hour and then 155 °C for 
4.5 hours.   Reaction was then cooled to room temperature. Unreacted amine was removed by Kugelrohr 
distillation at 120 °C under vacuum.  The remaining brown crude oil was then dissolved in CHCl3 and 
purified by preparative TLC using CHCl3/CH3OH/Et3N (25/1/1) as an eluent to yield CQ7a as a colorless 
oil (32%).  1H NMR (CDCl3) δ 8.62 (1H, d, 1-Ar-H), 8.23 (1H, d, 8-Ar-H), 7.91 (1H, d, 5-Ar-H), 7.58 
(1H, dd, 6-Ar-H), 6.52 (1H, d, 2-Ar-H), 5.55 (1H, m, Ar-NH), 3.75 (1H, m, -
NHCH(CH3)CH2CH2CH2N(CH2CH3)2),  2.56 (6H, m, -NHCH(CH3)CH2CH2CH2N(CH2CH3)2), 1.80 (2H, 
m, -NHCH(CH3)CH2CH2CH2N(CH2CH3)2), 1.67 (2H, m, -NHCH(CH3)CH2CH2CH2N(CH2CH3)2), 1.36 
(3H, d, -NHCH(CH3)CH2CH2CH2N(CH2CH3)2), 1.06 (6H, d, -NHCH(CH3)CH2CH2CH2N(CH2CH3)2). 
Synthesis of CQ7b.  CQ7b was synthesized using the same method as CQ4a using 4-chloroquinoline 
and 2-amino-5-diethylaminopentane (10%). 1H NMR (CDCl3) δ  8.53 (1H, d, 1-Ar-H), 7.97 (1H, d, 8-Ar-
H), 7.76 (1H, d, 5-Ar-H), 7.61 (1H, dd, 7-Ar-H), 7.40 (1H, d, 6-Ar-H), 6.42 (1H, d, 2-Ar-H), 5.21 (1H, br., 
Ar-NH), 3.75 (1H, m, -NHCH(CH3)CH2CH2CH2N(CH2CH3)2), 2.57-2.46 (6H, m, -
NHCH(CH3)CH2CH2CH2N(CH2CH3)2), 1.76 (2H, m, -NHCH(CH3)CH2CH2CH2N(CH2CH3)2), 1.62 (2H, 
m, -NHCH(CH3)CH2CH2CH2N(CH2CH3)2), 1.31 (3H, d, -NHCH(CH3)CH2CH2CH2N(CH2CH3)2), 1.08 
(6H, d, -NHCH(CH3)CH2CH2CH2N(CH2CH3)2).    
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Synthesis of CP.  4-Chloropyridine hydrochloride (1.0g, 6.66 mmol) and 2-amino-5-
diethylaminopentane (8.06 g, 50.88 mmol) were heated at 100oC for 1 hour, 155oC for 3 hours, and 135oC 
for 16 hours.   Reaction was then cooled to room temperature and the unreacted excess amine was 
removed by Kugelrohr distillation of the crude reaction mixture at 120oC under vacuum.   The remaining 
crude brown oil was then dissolved in CHCl3 and purified by preparative TLC using 
CHCl3/CH3OH/NH4OH (5/1/0.2) as an eluent to yield a colorless oil (24%) 1H NMR (CDCl3) δ 8.14 (1H, 
dd, 2,6-Py-H), 6.37 (1H, dd, 3,5-Py-H), 4.44 (1H, br., Py-NH), 3.51 (1H, m, -
NHCH(CH3)CH2CH2CH2N(CH2CH3)2), 2.54-2.41 (6H, m, -NHCH(CH3)CH2CH2CH2N(CH2CH3)2), 
1.18-1.54 (4H, m, -NHCH(CH3)CH2CH2CH2N(CH2CH3)2), 1.19 (3H, d, -
NHCH(CH3)CH2CH2CH2N(CH2CH3)2), 1.02 (6H, d, -NHCH(CH3)CH2CH2CH2N(CH2CH3)2). 
Synthesis of CQO.  NaH (60% dispersion in mineral oil, 0.234 g, 5.84 mmol) was added to a flame-
dried round bottom.  Anhydrous DMF (16.1 mL) was added to the flask under N2.  To this suspension 
was added dropwise a solution of N,N-diethyl-2-aminoethanol (0.71 mL, 5.35 mmol) in DMF (16.1 mL) 
and the resulting mixture was stirred 30 minutes (gas evolution had stopped).  A solution of 4,7-
dichloroquinoline (0.96 g, 4.87 mmol) in DMF (14.6 mL) was then added to the reaction.  Reaction was 
complete after 30 minutes as monitored by TLC.  The reaction mixture was then poured into 200 mL 
water.  The product was extracted with EtOAc (3 × 100mL).  The organic layer was then dried over 
Na2SO4, filtered, and concentrated under vacuum to give the title compound in 95% yield (1.29 g).  1H 
NMR (CDCl3) δ 8.72 (1H, d, 1-Ar-H), 8.12 (1H, d, 5-Ar-H), 8.0 (1H, d, 8-Ar-H), 7.44 (1H, dd, 6-Ar-H), 
6.74 (1H, d, 2-Ar-H), 4.28 (2H, t, -OCH2CH2N(CH2CH3)2), 3.15 (2H, t, -OCH2CH2N(CH2CH3)2), 2.71 
(4H, q, -OCH2CH2N(CH2CH3)2), 1.11 (6H, t, -OCH2CH2N(CH2CH3)2) 
Transfection of naked pDNA 
For cell transfection and luciferase assay, cells were plated at 5×104 cells/well in 24-well plates 24 h 
in advance.  Immediately prior to transfection, cells were rinsed once with PBS (pH 7.4), and 200 µL of 
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Opti-MEM (Gibco) was added to each well.  pGL3-CV (1 µg, 5 µL of a 0.2 µg/µL solution in DNAse-
free water) was mixed with an appropriate amount of CQ (or CQ analogues) solution, and were 
immediately transferred to each well.  After 4 h of incubation (37 °C, 5% CO2), the media in each well 
was replaced with 1 mL of culture media.  After another 44 h, the media was removed by aspiration.  
Cells were washed twice with PBS (pH 7.4) before addition of 100 µL of 1x cell culture lysis buffer 
(Promega).  Cell lysates were analyzed for luciferase activity with luciferase assay reagent (Promega).   
Light units were integrated over 10 s in duplicate with a luminometer (Monolight 2010, Analytical 
Luminescence Laboratory, San Diego, CA). 
The amount of protein in cell lysates obtained 48 h after transfection was used as a measure of cell 
viability. Protein levels of transfected cells were determined by the DC Protein Assay (Bio-Rad, Hercules, 
CA) and normalized with protein levels of cells transfected with naked DNA. A protein standard curve 
was run with various concentrations of bovine IgG (Bio-Rad) in cell culture lysis buffer.  
 
Figure S1. Effect of CQ analogues on transfection of HeLa cells with pDNA.  HeLa cells were 
transfected with pDNA in the presence of various CQ analogues (0.1 mM).  Luciferase activity was used 
as a measure of transfection efficiency. 
 
Transfection of CDP/pDNA in HepG2 cells in the presence of CQ and CQ analogues 
HepG2 cells were plated at 5×104 cells/well in 24-well plates 24 h in advance.  Immediately prior to 
transfection, cells were rinsed once with PBS (pH 7.4), and 200 µL of Opti-MEM (Gibco) was added to 
each well.  pGL3-CV (1 µg, 5 µL of a 0.2 µg/µL solution in DNAse-free water) was mixed with an equal 
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volume of polymer (5 µL of 24.9 mg/mL freshly prepared CDP solution in DNAse-free water) to give 
charge ratio 5 +/-.  Opti-MEM (185 µL) and an appropriate amount of CQ (or CQ analogues) in 5 µL 
Opti-MEM solution were mixed with CDP/pDNA complexes (10 µL) to give a final volume of 200 µL. 
These solutions were immediately transferred to each well.  After 4 h of incubation (37 °C, 5% CO2), the 
media in each well was replaced with 1 mL of culture media.  After another 44 h, the media was removed 
by aspiration.  Cells were washed twice with PBS (pH 7.4) before addition of 100 µL of 1 × cell culture 
lysis buffer (Promega).  Cell lysates were analyzed for luciferase activity with luciferase assay reagent 
(Promega).   Light units were measured in duplicate with a luminometer  (Monolight 2010, Analytical 
Luminescence Laboratory, San Diego, CA) (Figure S2) 
 The amount of protein in cell lysates obtained 48 h after transfection was used as a measure of cell 
viability. Protein levels of transfected cells were determined by the DC Protein Assay (Bio-Rad, Hercules, 
CA) and normalized with protein levels of cells transfected with naked DNA. A protein standard curve 
was run with various concentrations of bovine IgG (Bio-Rad) in cell culture lysis buffer (Figure S2).   
 a      b 
 
Figure S2.  Effect of CQ analogues on transfection of HepG2 cells.  HepG2 cells were transfected with 
CDP/pDNA polyplexes in the presence of various CQ analogues.  Luciferase activity was used as a 
measure of transfection efficiency (a) and total protein was used as a measure of cell viability (b). 
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Transfection of CDP/pDNA in BHK and A2780 cells in the presence of CQ and CQ analogues 
Transfection and expression of CDP/pDNA in BHK and A2780 cells in the presence or absence of 
CQ or CQ7a was similarly carried out as in HepG2 cells (see procedure in previous section) (Figure S3). 
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Figure S3.  Effect of CQ analogues on transfection of BHK and A2780 cells.  BHK or A2780 cells were 
transfected with CDP/pDNA polyplexes in the presence of CQ or CQ7a at variable concentrations.  
Luciferase activity was used as a measure of transfection efficiency (a) and total protein was used as a 
measure of cell viability (b). 
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Figure S4.  Effect of CQ and CQ7a on transfection of Poly-L-Lysine/pDNA in HepG2 cells.  HepG2 
cells were transfected in the presence of CQ or CQ7a at variable concentrations.  Luciferase activity was 
used as a measure of transfection efficiency (a) and total protein was used as a measure of cell viability 
(b). 
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Transfection of Poly-lysine (MW 15-30 kDa, Sigma)/pDNA (N/P = 15/1) in HepG2 cells (Figure 
S4) in the presence of CQ and CQ7a is similarly carried out as CDP/pDNA in HepG2 cells (see previous 
description). 
Uptake of polyplexes in the absence or presence of CQ analogues 
 
Figure S5  Flow cytometry analysis of polyplex uptake in the presence of CQ analogues.  pDNA labeled 
with Alexa-fluor-488 was condensed with CDP and administered to HepG2 cells. Uptake was terminated 
at 30 min and 2 h and cells were analyzed by flow cytometry.  Uptake of polyplexes was similar in the 
absence of any CQ analogue (a) or in the presence of 200 µM CQ (b), 200 µM CQ7b (c), or 200 µM 
CQ7a (d).  The cellular fluorescence was analyzed at 0 min (I), 30 min (II), or 2 h (III). 
 
 pDNA was prepared for fluorophore binding by reacting with Label-IT Amine (Mirus, Madison, WI).  
After 1 hour at 37 °C, the amine-terminated DNA was recovered by precipitation with ethanol, then 
incubated overnight with Alexa-fluor-488 NHS ester (Molecular Probes, Eugene, OR).  The labeled DNA 
was purified by precipitation with ethanol.  The percentage of pDNA labeling was determined to be 3.3 
  
 
S9 
 
wt% by measuring the fluorescence intensity of labeled DNA (λexcitation 488 nm; λemission 535 nm) 
using a Spectrafluor Plus plate reader (Tecan, Durham, NC) and comparing with a standard curve. 
 Labeled pDNA was condensed with CDP prior to being administered to HepG2 cells at a 
concentration 5 µg DNA/mL culture medium (same concentration as in gene transfection study).  Uptake 
was terminated at 30 min and at 2 hours.  Cells were treated with 0.25% trypsin, washed with phosphate-
buffered saline and Hanks balanced salt solution, and analyzed by fluorescence-activated cell sorting 
(FACS) (Figure S5). 
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